menu search

Nkarta (nktx) rallies 112% as fda clears ind for lupus drug

Nkarta (NKTX) rallies 112% on FDA nod to begin the clinical development of its investigational candidate, nkx0...

October 18, 2023, 12:03 pm

Nkarta reports second quarter 2023 financial results and corporate highlights

NKX101 clinical update highlights encouraging antileukemic activity in patients with AML using fludarabine/cytarabine (Flu/Ara-C) lymphodepletion regi...

August 10, 2023, 11:01 am

Nkarta presents nkx019 clinical data at the european hematology association 2023 congress and 17th international conference on malignant lymphoma

7 of 10 r/r NHL patients achieved complete response (70% CR rate) following treatment with nkx019 monot...

June 10, 2023, 2:47 pm

Nkarta to host conference call to discuss updated clinical data from nkx019 nk cell therapy program

Call scheduled for Monday, December 5, 2022 at 8:00 a.m. ET SOUTH SAN FRANCISCO, Calif., Dec. 02, 2022 (GLOBE NEWSWIRE) — Nkarta, Inc. (Nasdaq: NKTX...

December 2, 2022, 9:02 pm

Nkarta to host conference call to discuss updated clinical data from nkx019 nk cell therapy program

Call scheduled for Monday, December 5, 2022 at 8:00 a.m. ET Call scheduled for Monday, December 5, 2022 at 8:00 a.m. ET...

December 2, 2022, 4:02 pm

Nkarta: a promising natural killer cell play

The market has favorably appreciated Nkarta's recent readout of its NKX101 and nkx019 drug candidates, ...

May 20, 2022, 3:14 pm

Here is why nkarta is 40% up

Nkarta Inc. (NASDAQ: NKTX) is up 40% after announcing positive preliminary Phase 1 findings from its dose-finding trials of NKX101 and ...

April 25, 2022, 12:51 pm


Search within

Pages Search Results: